Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer

被引：0
|
作者：
Shuangjie Liu
Zhuonan Liu
Chiyuan Piao
Zhe Zhang
Chuize Kong
Lei Yin
Xi Liu
机构：
[1] The First Hospital of China Medical University,Department of Urology
来源：
Journal of Experimental & Clinical Cancer Research | / 41卷
关键词：
Protein arginine methyltransferase; Flavokawain A; Bladder cancer; Methylation disorder; Arginine methylation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] A complex signature network that controls the upregulation of PRMT5 in colorectal cancer
    Wei, Han
    Hartley, Antja-Voy
    Motolani, Aishat
    Jiang, Guanglong
    Safa, Ahmad
    Prabhu, Lakshmi
    Liu, Yunlong
    Lu, Tao
    GENES & DISEASES, 2022, 9 (02) : 285 - 287
  • [42] Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer
    Poulard, Coralie
    Pham, Thuy Ha
    Drouet, Youenn
    Jacquemetton, Julien
    Surmielova, Ausra
    Kassem, Loay
    Mery, Benoite
    Lasset, Christine
    Reboulet, Jonathan
    Treilleux, Isabelle
    Marangoni, Elisabetta
    Tredan, Olivier
    Le Romancer, Muriel
    EMBO MOLECULAR MEDICINE, 2023, 15 (08)
  • [43] The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond
    Stopa, Nicole
    Krebs, Jocelyn E.
    Shechter, David
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2015, 72 (11) : 2041 - 2059
  • [44] PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer
    Zhe Wang
    Jing Kong
    Ying Wu
    Juliang Zhang
    Ting Wang
    Nanlin Li
    Jing Fan
    Hui Wang
    Jian Zhang
    Rui Ling
    Breast Cancer Research and Treatment, 2018, 168 : 531 - 542
  • [45] The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond
    Nicole Stopa
    Jocelyn E. Krebs
    David Shechter
    Cellular and Molecular Life Sciences, 2015, 72 : 2041 - 2059
  • [46] Inhibition of PRMT5 results in radiosensitization in lung cancer cell lines
    Sharma, Smitha
    Wu, X.
    Smith, P.
    Denko, N.
    Li, C.
    Lai, H.
    Yan, F.
    Shilo, K.
    Chakravarti, A.
    Sif, S.
    Baiocchi, R.
    Otterson, G.
    Xu-Welliver, Meng
    CANCER RESEARCH, 2014, 74 (19)
  • [47] PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer
    Wang, Zhe
    Kong, Jing
    Wu, Ying
    Zhang, Juliang
    Wang, Ting
    Li, Nanlin
    Fan, Jing
    Wang, Hui
    Zhang, Jian
    Ling, Rui
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (02) : 531 - 542
  • [48] Novel, small-molecule PRMT5 inhibitors for treatment of cancer
    Sivanandhan, Dhanalakshmi
    Garapaty, Shivani
    Vadivelu, Saravanan
    Seerapu, Guru Pavan Kumar
    Das, Reshma
    Kar, Ronodip
    Singh, Anuj Kumar
    Venkateshappa, Venkatesha Ashokkumar
    Tamizharasan, Natarajan
    Swamy, Indu N.
    Nagaraju, Nagendra
    Kanagaraj, Subramaniyam
    Sarkar, Sayanti
    Tibhe, Jagadish D.
    Rudresh, G.
    Zainuddin, Mohd
    Kandan, Saravanan
    Rajagopal, Sridharan
    Rajagopal, Sriram
    CANCER RESEARCH, 2018, 78 (13)
  • [49] PRMT5 selective inhibitor enhances therapeutic efficacy of cisplatin in lung adenocarcinoma cells
    Bajbouj, Khuloud
    Ramakrishnan, Rakhee
    Ihmaid, Ahmed M. H.
    Ali, Suhaib Al Haj
    Alalool, Abdulla
    Abdullah, Reem
    Saber-Ayad, Maha
    Hamid, Qutayba
    CANCER RESEARCH, 2019, 79 (13)
  • [50] Scalable Atroposelective Synthesis of MRTX1719: An Inhibitor of the PRMT5/MTA Complex
    Achmatowicz, Michal
    Scattolin, Thomas
    Snead, David R.
    Paymode, Dinesh J.
    Roshandel, Sahar
    Xie, Chen
    Chen, Guihui
    Chen, Cheng-yi
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2023, 27 (05) : 954 - 971
12345